Emerging Challenges in Primary Care: 2018

Transcription

1 Uniondale Simulcast 2018 Cover.qxp_Cover 9/25/18 9:31 AM Page 1 17th Annual Emerging Challenges in Primary Care: 2018 LIVE CONFERENCE Saturday, October 6, 2018 Broadcast Live from Uniondale, NY Provided by

2 COPYRIGHT 2018 All rights reserved. No part of this book, except those portions specifically noted, may be reproduced or transmitted in any form or by any means now known or to be invented, electronic or mechanical, including photocopying, recording, or by any information storage or retrieval system without written permission from the authors, except for the brief inclusion of quotations in a review. Requests for permission or further information should be addressed to the author(s) of each presentation. National Association for Continuing Education 300 NW 70 th Avenue, Suite 102 Plantation, Florida (954) Printed in the United States of America.

3 Table of Contents A Message from the Course Director 2 Agenda 3 Course Faculty and Planning Committee 4 CME/CE Information 6 Accreditation and Designation Statements How to Claim Your CME Credit Disclosure Policy Summary of Individual Disclosures Disclosure of Commercial Support Americans with Disabilities Presentations* Getting Comfortable with Insulin: New Approaches to Getting Patients Safely to Target 9 Management of Nocturia: An Unmet Need in LUTS 11 Safe Means of Administering the Right Therapy Extended-Release and Long-Acting 13 Opioids (Get SMART Part I and II) Recognition and Management of Primary Biliary Cholangitis (PBC): A Chronic 15 Inflammatory Liver Disease Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early 17 Diagnosis Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care 19 * Full slide presentations are available for download at 1

4 A Message from the Course Director 300 NW 70 th Avenue Suite 102 Plantation, Florida (954) Phone (954) Fax internet: s a primary care physician, I know first-hand the complex challenges that primary care providers face everyday in their busy practices. I also know that with rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice. One of the key messages to be discussed this year will be communication strategies to allow a better understanding of our patients and help them manage their diseases more effectively. Topics to be addressed will include diabetes, nocturia, opioids, liver disease, interstitial lung disease, and lipids. To reach this goal we have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning. We invite you to engage with our faculty and share your ideas in peer-to-peer dialogue. We know you will leave with new ideas, skills, and tools to help your patients. Enjoy the conference! Gregg Sherman, MD Chief Medical Officer National Association for Continuing Education 2

5 Agenda 7:20-7:50 am Continental Breakfast and Registration 7:50 8:00 Welcome Remarks Jack Kravitz, MD 8:00 9:30 Getting Comfortable with Insulin: New Approaches to Getting Patients Safely to Target Javier Morales, MD 9:30 10:30 Management of Nocturia: An Unmet Need in LUTS David R. Staskin, MD 10:30 10:50 Break 10:50 12:05 Safe Means of Administering the Right Therapy Extended-Release and Long-Acting Opioids (Get SMART Part I) Michael R. Clark, MD, MPH, MBA and Yvonne D'Arcy, MS, ARNP-C, CNS, FAANP 12:05 1:05 Lunch (on your own) 1:05 2:20 Safe Means of Administering the Right Therapy Extended-Release and Long-Acting Opioids (Get SMART Part II) Michael R. Clark, MD, MPH, MBA and Yvonne D'Arcy, MS, ARNP-C, CNS, FAANP 2:20 3:20 Recognition and Management of Primary Biliary Cholangitis (PBC): A Chronic Inflammatory Liver Disease Kalyan Ram Bhamidimarri, MD, MPH 3:20 3:30 Break 3:30 4:30 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Arunabh Talwar, MD, FCCP 4:30 5:30 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Ola Akinboboye, MD, MPH, MBA 3

6 Course Faculty and Planning Committee Chief Medical Officer and Course Director Gregg Sherman, MD Emerging Challenges in Primary Care National Association for Continuing Education Plantation, FL Faculty Ola Akinboboye, MD, MPH, MBA Associate Professor of Clinical Medicine Cornell University Past President, Association of Black Cardiologists Medical Director, Queens Heart Institute Rosedale, NY Kalyan Ram Bhamidimarri, MD, MPH Transplant Hepatologist, University of Miami Medical Director of Small Bowel & Multi-visceral Transplantation Miami Transplant Institute Miami, FL Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY Michael R. Clark, MD, MPH, MBA Chair, Psychiatry & Behavioral Health Inova Health System Falls Church, VA Yvonne D'Arcy, MS, ARNP-C, CNS, FAANP Pain Management Nurse Practitioner Ponte Vedra Beach, FL Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH Professor of Medicine, Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine University of Michigan Ann Arbor, MI Rodolfo J. Galindo, MD Assistant Professor of Medicine Emory University School of Medicine Principal Investigator, Center for Diabetes and Metabolism Research Division of Endocrinology, Diabetes and Metabolism Emory University Hospital Midtown Medical Chair, Hospital Diabetes Taskforce Emory Healthcare System Atlanta, GA Robert L. Gillespie, MD, FACC, FASE, FASNC Immediate Past Chairman of the Board, Association of Black Cardiologists Director of Nuclear Imaging, Sharp Rees-Stealy Medical Group San Diego, CA Jack Kravitz, MD Family Practice - Geriatrics Coral Springs, FL Davida F. Kruger, MSN, APN-BC, BC-ADM Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease Detroit, MI David J. Lederer, MD, MS Associate Professor of Medicine & Epidemiology Co-Director, Interstitial Lung Disease Program Columbia University Medical Center New York, NY Fernando J. Martinez, MD, MS Chief, Division of Pulmonary and Critical Care Medicine Bruce Webster Professor of Medicine Joan and Sanford I. Weill Department of Medicine Weill Cornell Medical College New York-Presbyterian Hospital/Weill Cornell Medical Center New York, NY Javier Morales, MD, FACP, FACE Clinical Associate Professor of Medicine Donald and Barbara Zucker School of Medicine At Hofstra/Northwell University Vice President Advanced Internal Medicine Group, P.C. East Hills, NY David Montgomery, MD, PhD, FACC Preventive Cardiologist Piedmont Heart Institute Atlanta, GA Deborah Paschal, CRNP Clinical Nurse Practitioner Philadelphia, PA Franck Rahaghi, MD, MHS, FCCP Director of Advanced Lung Disease Clinic Director, Pulmonary Hypertension Clinic Chairman, Dept. of Pulmonary and Critical Care Cleveland Clinic Florida Weston, FL Matt T. Rosenberg, MD, Director, Mid-Michigan Health Centers Jackson, MI 4

7 Mark Stolar, MD Associate Professor of Clinical Medicine Northwestern University Medical School Chicago, IL Robert A. Sandhaus, MD, PhD, FCCP Professor of Medicine Director, Alpha-1 Program National Jewish Health Clinical Director, Alpha-1 Foundation Executive VP and Medical Director, AlphaNet Medical Director, AlphaNet Canada Coral Gables, FL David R. Staskin, MD Associate Professor of Urology Tufts University School of Medicine Director, Center for Male and Female Pelvic Health St. Elizabeth s Medical Center Boston, MA Arunabh Talwar, MD, FCCP Director, Pulmonary Hypertension and Advanced Lung Disease Program North Shore University Hospital Manhasset, New York Professor of Medicine, Donald and Barbara Zucker School of Medicine Hofstra Northwell Hofstra University Hempstead, NY Jeff Unger, MD, FAAFP, FACE Assistant Clinical Professor of Family Medicine UC Riverside School of Medicine Director, Unger Concierge Primary Care Medical Group Rancho Cucamonga, CA Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology Director, UCLA Barbra Streisand Women s Heart Health Program Los Angeles, CA Marlene R. Wolf, MD, FAAFP Clinical Assistant Professor of Family Medicine Nova Southeastern University's College of Allopathic Medicine Family Practice Lifetime Medical Consulting, LLC Coral Springs, FL Staff and Planning Committee Sandy Bihlmeyer, M.Ed. National Association for Continuing Education Plantation, FL Dean Beals President & CEO DKBmed New York, NY Rachel Deerr Program Manager DKBmed New York, NY Michelle Frisch, MPH, CHCP National Association for Continuing Education Plantation, FL Alan Goodstat, LCSW National Association for Continuing Education Plantation, FL Joshua F. Kilbridge President and Creative Director Kilbridge Associates San Francisco, CA Sheila Lucas, CWEP National Association for Continuing Education Plantation, FL Cassandra A. McCullough, MBA Chief Executive Officer Association of Black Cardiologists New York, NY Cedric Nazareth, MBBS Medical Writer Cedric Nazareth Medical Writing Mississauga, ON Harvey C. Parker, PhD, CHCP Director of Continuing Education National Association for Continuing Education Plantation, FL Stan J. Pogroszewski, JD COO/Director of Compliance DKBmed New York, NY Gregg Sherman, MD Chief Medical Officer National Association for Continuing Education Plantation, FL 5

8 CME/CE Information Accreditation and Designation Statement The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Association for Continuing Education designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number This program has been approved for 5.5 contact hours of continuing education (which includes 2.75 pharmacology hours). Joint Accreditation Statement Postgraduate Institute for Medicine In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and DKBmed. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Continuing Medical Education The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 2.5 contact hours. Designated for 2.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. Method of Participation for learners who will be requesting credit for the REMS sessions Request for Credit if you wish to receive AMA or ANCC credit If you wish to receive acknowledgment for completing this activity, please complete the evaluation on On the navigation menu, click on Find Post-test/Evaluation by Course and search by course ID Upon registering and completing the activity evaluation, your certificate will be made available immediately. How do I claim CME credit for this activity? To claim CME credit for your participation today, you need to complete and submit the evaluation form included in your handout and you will need to claim your credits online. Within 2 weeks, NACE will send you an with instructions on how to claim your CME credits online and print your CME certificate. Disclosure Policy It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials. Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this 6

9 activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity. Summary of Individual Disclosures Ola Akinboboye, MD, MPH, MBA Dean Beals Kalyan Ram Bhamidimarri, MD, MPH Sandy Bihlmeyer, M.Ed. Robert S. Busch, MD, FACE Michael R. Clark, MD, MPH, MBA Yvonne D'Arcy, MS, ARNP-C, CNS, FAANP Rachel Deerr Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH Kevin Flaherty, MD, MS Michelle Frisch, MPH, CHCP Rodolfo J. Galindo, MD Robert L. Gillespie, MD, FACC, FASE, FASNC Alan Goodstat, LCSW Joshua F. Kilbridge Jack Kravitz, MD Davida F. Kruger, MSN, APN-BC,BC- ADM David J. Lederer, MD, MS Sheila Lucas, CWEP Fernando J. Martinez, MD, MS Cassandra A. McCullough, MBA Javier Morales, MD, FACP, FACE David Montgomery, MD, PhD, FACC Cedric Nazareth, MBBS Deborah Paschal, CRNP Harvey Parker, Ph.D., CHCP Stan J. Pogroszewski, JD Franck Rahaghi, MD, MHS, FCCP Matt T. Rosenberg, MD Robert A. Sandhaus, MD, PhD, FCCP Gregg Sherman, MD David R. Staskin, MD Mark Stolar, MD Arunabh Talwar, MD, FCCP Jeff Unger, MD, FAAFP, FACE Karol E. Watson, MD, PhD Marlene R. Wolf, MD, FAAFP Scientific Advisory board - Gilead, AbbVie, Merck, Intercept Speaker/Teacher - Novo Nordisk, Sanofi, Astra Zeneca, Boehringer Ingelheim Royalty - Springer Publishing-books; Consulting Fees - Egalet, Purdue, Practicing Clinicians Exchange, Ortho-Mcneil; Fees for Non-CME/CE Services - Purdue-non branded materials Consultant - Amgen, Boehringer Ingelheim, Sanofi, Novartis, Quantum Genomics Consultant - Boehringer Ingelheim, Veracyte, Roche/Genentech, FibroGen, Sanofi Genzyme Consultant/Speaker - Boston Scientific Advisory Board - Novo Nordisk, Abbott, Eli Lilly and Company, Sanofi Adventis, Janssen, Dexcom, Intarcia; Speakers Bureau -Janssen, Valeritas, AZ, BI/Lilly, Novo Nordisk, Dexcom, Lilly, Abbott, Insulet; Grants Research - AZ, Eli Lilly, Novo Nordisk, Hemsley Foundation, Dexcom, Lexicom, Abbott; Stock - Dexcom Consultant - Veracyte Advisory Boards - Astra Zeneca, Boehringer Ingelheim, Chicsi, GSK, Sunovion, Zambon; Study Steering Comittee - Astra Zeneca, Boehringer Ingelheim, Bayer, Biogern, Gilead, GSK, Nitto, ProMetic, Veracyte; Data and Safety Monitoring Board - Boehringer Ingelheim, Biogen, Genentech Speakers Bureau/Consultant - Lilly, Novo Nordisk, Janssen, Abbott Speaker - Novartis (ILD) Consultant/Speaker Boehringer Ingelheim, Genentech (AATD) Speaker/Consultant /Researcher for Shire; Speaker/Consultant for Grifols Advisory Committee - Avadel, Opko, Ferring, Astellas Principal Investigator - NIH/NHLBI, MatRx Investigator - GTX, Urovant; Consultant - Ferring; Speaker/Consultant/Investigator - Astellas Pharma Speakers Bureau - AstraZeneca Speaker - Boehringer Ingelheim; Advisory Board - Genentech Consultant, Research, Advisory Board - Novo Nordisk, Janssen, Abbott Diabetes Consultant - Amgen, Bayer, Boehringer Ingelheim, Kowa Consultant - Lifetime Medical; Independent Consultant - Consulting, LLC. 7

10 Disclosure of Commercial Support This educational activity is supported, in part, by educational funding provided by Amgen, an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc., an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.; an educational grant from Ferring Pharmaceuticals, Inc.; an educational grant from Intercept Pharmaceuticals; an educational grant from Sanofi US; and an educational grant from Sanofi US and Regeneron Pharmaceuticals. This activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA). PIM Disclosure Information The PIM planners and managers have nothing to disclose. Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Target Audience This activity is intended for primary care physicians delivering primary care to adults. Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer s product information, and comparison with recommendations of other authorities. Americans With Disabilities Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific needs. 8

11 Getting Comfortable with Insulin: New Approaches to Getting Patients Safely to Target Learning Objectives Identify the barriers between clinicians and patients to discussing and initiating earlier insulin therapy for diabetes management. Discuss currently available basal and ultrabasal insulins and their pharmacokinetic/ pharmacodynamic profiles. Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk. Describe how best to initiate, utilize and intensify insulin therapy in patients with diabetes while incorporating treatment guidelines and unique patient needs. Integrate strategies to improve the patient experience with, and adherence to, insulin therapy. Faculty Members The faculty members listed below contributed to the development of the content being presented. One of these individuals will present the content today. Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY Davida F. Kruger, MSN, APN-BC, BC-ADM Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease Detroit, MI Rodolfo J. Galindo, MD Assistant Professor of Medicine Emory University School of Medicine Principal Investigator, Center for Diabetes and Metabolism Research Division of Endocrinology, Diabetes and Metabolism Emory University Hospital Midtown Medical Chair, Hospital Diabetes Taskforce Emory Healthcare System Atlanta, GA Javier Morales, MD, FACP, FACE Clinical Associate Professor of Medicine Donald and Barbara Zucker School of Medicine At Hofstra/Northwell University Vice President Advanced Internal Medicine Group, P.C. East Hills, NY Jeff Unger, MD, FAAFP, FACE Assistant Clinical Professor of Family Medicine UC Riverside School of Medicine Director Unger Concierge Primary Care Medical Group Rancho Cucamonga, CA Mark Stolar, MD Associate Professor of Clinical Medicine Feinberg School of Medicine Northwestern University Chicago, IL Slides are available for download at: 9

12 KEY NOTES WHAT SHOULD I IMPLEMENT IN MY PRACTICE? 10

13 Management of Nocturia: An Unmet Need in LUTS Learning Objectives Describe the impact of nocturia on affected patients. Evaluate symptoms of nocturia in affected patients. Assess current pharmacologic and nonpharmacologic nocturia management strategies. Differentiate the mechanisms of action and safety and efficacy profiles of available and emerging therapies for nocturia. Faculty Members The faculty members listed below contributed to the development of the content being presented. One of these individuals will present the content today. Matt T. Rosenberg, MD Director, Mid-Michigan Health Centers Jackson, MI David R. Staskin, MD Associate Professor of Urology Tufts University School of Medicine Director, Center for Male and Female Pelvic Health St. Elizabeth s Medical Center Boston, MA Slides are available for download at: 11

14 KEY NOTES WHAT SHOULD I IMPLEMENT IN MY PRACTICE? 12

15 Safe Means of Administering the Right Therapy Extended- Release and Long-Acting Opioids (Get SMART Part I and II) Learning Objectives Assess patients for treatment with ER/LA opioid analgesics. Evaluate and initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics. Manage ongoing therapy with ER/LA opioid analgesics. Perform effective counseling with patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal. Identify general and product-specific drug information concerning ER/LA opioid analgesics. Faculty Members The faculty members listed below contributed to the development of the content being presented. One of these individuals will present the content today. Michael R. Clark, MD, MPH, MBA Chair, Psychiatry & Behavioral Health Inova Health System Falls Church, VA Yvonne D'Arcy, MS, ARNP-C, CNS, FAANP Pain Management Nurse Practitioner Ponte Vedra Beach, FL Slides are available for download at: 13

16 KEY NOTES WHAT SHOULD I IMPLEMENT IN MY PRACTICE? 14

17 Recognition and Management of Primary Biliary Cholangitis (PBC): A Chronic Inflammatory Liver Disease Learning Objectives Review the epidemiology of primary biliary cholangitis (PBC). Describe the pathophysiology of PBC. Recognize how to evaluate a patient for PBC. Discuss the treatment of PBC, including the treatment of extrahepatic manifestations. Faculty Members The faculty member listed below contributed to the development of the content being presented. This individual will present the content today. Kalyan Ram Bhamidimarri, MD, MPH Transplant Hepatologist, University of Miami Medical Director of Small Bowel & Multi-visceral Transplantation Miami Transplant Institute Miami, FL Slides are available for download at: 15

18 KEY NOTES WHAT SHOULD I IMPLEMENT IN MY PRACTICE? 16

19 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Learning Objectives Recognize the importance of early identification of patients with potential idiopathic pulmonary fibrosis (IPF). Utilize appropriate strategies to diagnose a patient with IPF while excluding other potential mimickers. Discuss the available therapeutic options for patients with IPF. Recognize the role of the primary care clinician in managing the multi-morbidities associated with IPF. Faculty Members The faculty members listed below contributed to the development of the content being presented. One of these individuals will present the content today. Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine University of Michigan Ann Arbor, MI David J. Lederer, MD, MS Associate Professor of Medicine & Epidemiology Co-Director, Interstitial Lung Disease Program Columbia University Medical Center New York, NY Fernando J. Martinez, MD, MS Chief, Division of Pulmonary and Critical Care Medicine Bruce Webster Professor of Medicine Joan and Sanford I. Weill Department of Medicine Weill Cornell Medical College New York-Presbyterian Hospital/Weill Cornell Medical Center New York, NY Franck Rahaghi, MD, MHS, FCCP Director of Advanced Lung Disease Clinic Director, Pulmonary Hypertension Clinic Chairman, Dept. of Pulmonary and Critical Care Cleveland Clinic Florida Weston, FL Arunabh Talwar, MD, FCCP Director, Pulmonary Hypertension and Advanced Lung Disease Program North Shore University Hospital, Manhasset, New York Professor of Medicine Donald and Barbara Zucker School of Medicine Hofstra/ Northwell Hofstra University Hempstead, NY Slides are available for download at: 17

20 KEY NOTES WHAT SHOULD I IMPLEMENT IN MY PRACTICE? 18

21 Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care Learning Objectives Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes. Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients. Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk. Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them. Faculty Members The faculty members listed below contributed to the development of the content being presented. One of these individuals will present the content today. Ola Akinboboye, MD, MPH, MBA Associate Professor of Clinical Medicine Cornell University Past President, Association of Black Cardiologists Medical Director, Queens Heart Institute Rosedale, NY Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH Professor of Medicine, Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA David Montgomery, MD, PhD, FACC Preventive Cardiologist Piedmont Heart Institute Atlanta, GA Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology Director, UCLA Barbra Streisand Women s Heart Health Program Los Angeles, CA Robert L. Gillespie, MD, FACC, FASE, FASNC Immediate Past Chairman of the Board, Association of Black Cardiologists Director of Nuclear Imaging, Sharp Rees-Stealy Medical Group San Diego, CA Slides are available for download at: 19

22 KEY NOTES WHAT SHOULD I IMPLEMENT IN MY PRACTICE? 20